|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002766,
umls-concept:C0010132,
umls-concept:C0017262,
umls-concept:C0040300,
umls-concept:C0185117,
umls-concept:C0205100,
umls-concept:C0205102,
umls-concept:C0242402,
umls-concept:C0333348,
umls-concept:C1514873,
umls-concept:C1546857,
umls-concept:C1556066,
umls-concept:C1619636,
umls-concept:C2911684
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1996-7-25
|
|
pubmed:abstractText |
Immune cell-derived opioid peptides can activate opioid receptors on peripheral sensory nerves to inhibit inflammatory pain. The intrinsic mechanisms triggering this neuroimmune interaction are unknown. This study investigates the involvement of endogenous corticotropin-releasing factor (CRF) and interleukin-1beta (IL-1). A specific stress paradigm, cold water swim (CWS), produces potent opioid receptor-specific antinociception in inflamed paws of rats. This effect is dose-dependently attenuated by intraplantar but not by intravenous alpha-helical CRF. IL-1 receptor antagonist is ineffective. Similarly, local injection of antiserum against CRF, but not to IL-1, dose-dependently reverses this effect. Intravenous anti-CRF is only inhibitory at 10(4)-fold higher concentrations and intravenous CRF does not produce analgesia. Pretreatment of inflamed paws with an 18-mer 3'-3'-end inverted CRF-antisense oligodeoxynucleotide abolishes CWS-induced antinociception. The same treatment significantly reduces the amount of CRF extracted from inflamed paws and the number of CRF-immunostained cells without affecting gross inflammatory signs. A mismatch oligodeoxynucleotide alters neither the CWS effect nor CRF immunoreactivity. These findings identify locally expressed CRF as the predominant agent to trigger opioid release within inflamed tissue. Endogenous IL-1, circulating CRF or antiinflammatory effects, are not involved. Thus, an intact immune system plays an essential role in pain control, which is important for the understanding of pain in immunosuppressed patients with cancer or AIDS.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-1281840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-1319455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-1385928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-1392536,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-1603330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-1838480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-1925600,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-1974052,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-2045122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-2158530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-2163323,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-2354999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-3030699,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-3274895,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-3708354,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-6505691,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-7556397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-7688879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-7760870,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-7910403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-7969490,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8650225-8494356
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
11
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6096-100
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8650225-Analgesics, Opioid,
pubmed-meshheading:8650225-Animals,
pubmed-meshheading:8650225-Base Sequence,
pubmed-meshheading:8650225-Corticotropin-Releasing Hormone,
pubmed-meshheading:8650225-Immunohistochemistry,
pubmed-meshheading:8650225-Inflammation,
pubmed-meshheading:8650225-Interleukin-1,
pubmed-meshheading:8650225-Male,
pubmed-meshheading:8650225-Molecular Sequence Data,
pubmed-meshheading:8650225-Naloxone,
pubmed-meshheading:8650225-Oligonucleotides, Antisense,
pubmed-meshheading:8650225-Pain,
pubmed-meshheading:8650225-Radioimmunoassay,
pubmed-meshheading:8650225-Rats,
pubmed-meshheading:8650225-Rats, Wistar
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia.
|
|
pubmed:affiliation |
Behavioral Pharmacology and Genetics Section, Division of Intramural Research, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 21224, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
